“We plan to launch this product first in the US market, where one third of the adult population is obese and total amount spent on obesity amounts to 450 billion USD annually,” said Sung-Ho Han, CEO of Olive Healthcare. And he said, “CES will be a great opportunity to do pre-marketing our product to US customers.”
For your information, Olive Healthcare is focusing on digital healthcare solutions and medical diagnostic devices based on monitoring the body’s physiological changes by non-invasively quantifying oxy-hemoglobin, deoxy-hemoglobin, lipid, and water using their DMW-NIRS (Discrete Multi-Wavelength Near Infra-Red Spectroscopy) technology. In addition to those health-related critical biomarkers, they will give personalized service based on big-data analysis. In 2019, they will commercialize the belly fat scanner and begin clinical trials on breast tissue malignancy.
한성호 대표는 “성인 인구의 30% 이상이 비만이고 비만으로 인한 사회적 비용이 매년 450조원인 북미시장에 이 제품을 먼저 출시할 계획”이라며 “CES는 미국 소비자에게 우리 제품을 알릴 수 있는 좋은 기회”라고 말했다.